Aligos says partner Amoytop doses first participant in Phase 1 trial of HBV drug ALG-170675 in China

Aligos says partner Amoytop has begun dosing the first participant in a Phase 1 trial of ALG-170675, an investigational antisense drug for chronic hepatitis B functional cure.

• No clinical results were reported; initial readouts will come later as the study evaluates safety, tolerability, pharmacokinetics, pharmacodynamics.
• The trial in China is run by partner Amoytop, which holds Greater China rights; single-ascending, multiple-ascending dosing is planned in healthy volunteers.
• Move into chronic HBV patients is planned for Q4 2026, positioning the program for potential combination regimens in the region.